Drug Profile
Tangier disease gene therapy - Aventis
Latest Information Update: 08 Jul 2002
Price :
$50
*
At a glance
- Originator Aventis; Nonindustrial source
- Developer Nonindustrial source
- Class Antihyperlipidaemics; Gene therapies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Tangier disease
Most Recent Events
- 23 Dec 1999 Rhône-Poulenc Rorer has merged with Hoechst Marion Roussel to form Aventis Pharma
- 06 Aug 1999 New profile
- 06 Aug 1999 Preclinical development for Tangier disease in Germany (Unknown route)